Cystic fibrosis gene therapy - GlaxoSmithKline/Valentis

Drug Profile

Cystic fibrosis gene therapy - GlaxoSmithKline/Valentis

Alternative Names: GR 213487B; MB121

Latest Information Update: 21 Mar 2001

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Valentis
  • Class Gene therapies
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 21 Mar 2001 Discontinued-II for Cystic fibrosis in USA (Intranasal)
  • 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
  • 22 Jun 1999 The Megabios/GeneMedicine merged company is now called Valentis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top